Structure Therapeutics Inc. (NASDAQ:GPCR) Holdings Lifted by Fmr LLC

Fmr LLC grew its holdings in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) by 6.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,128,444 shares of the company’s stock after buying an additional 383,635 shares during the period. Fmr LLC owned 10.71% of Structure Therapeutics worth $268,977,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Bank of Montreal Can acquired a new position in Structure Therapeutics during the 2nd quarter worth $1,064,000. Lighthouse Investment Partners LLC acquired a new stake in Structure Therapeutics in the second quarter worth about $1,178,000. abrdn plc grew its position in Structure Therapeutics by 132.7% in the 3rd quarter. abrdn plc now owns 217,083 shares of the company’s stock valued at $9,528,000 after buying an additional 123,789 shares in the last quarter. First Light Asset Management LLC increased its stake in Structure Therapeutics by 296.1% during the 2nd quarter. First Light Asset Management LLC now owns 590,647 shares of the company’s stock valued at $23,195,000 after buying an additional 441,534 shares during the period. Finally, Blue Owl Capital Holdings LP bought a new stake in shares of Structure Therapeutics during the 2nd quarter worth about $2,160,000. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Structure Therapeutics Stock Performance

Shares of NASDAQ:GPCR opened at $33.15 on Monday. The company has a market capitalization of $1.90 billion, a PE ratio of -44.80 and a beta of -3.23. The stock has a fifty day moving average of $38.21 and a 200-day moving average of $39.45. Structure Therapeutics Inc. has a one year low of $26.61 and a one year high of $66.38.

Analysts Set New Price Targets

Several research analysts have recently issued reports on GPCR shares. Morgan Stanley started coverage on shares of Structure Therapeutics in a report on Monday, September 23rd. They issued an “overweight” rating and a $118.00 price objective for the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $65.00 price objective on shares of Structure Therapeutics in a research note on Monday, September 23rd. Finally, JMP Securities decreased their target price on Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating for the company in a research note on Friday, August 9th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, Structure Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $86.80.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.